Robert J. Motzer
Kidney-cancer oncologist who led the RECORD-1 phase III trial showing that the mTOR inhibitor everolimus extends progression-free survival in metastatic renal cell carcinoma.
Section Head, Kidney Cancer, Genitourinary Oncology Service & Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center (New York, New York, USA) ↗
Portrait: Memorial Sloan Kettering Cancer Center
Robert Motzer is a medical oncologist at Memorial Sloan Kettering Cancer Center in New York who heads its kidney cancer section. According to the MSK profile he has led more than 80 clinical trials, mostly in kidney and testicular cancer, and he chairs the NCCN guidelines panel for kidney cancer.
MOT2008 is the RECORD-1 trial, with Motzer as first author in The Lancet. Patients with metastatic renal cell carcinoma whose disease had progressed on sunitinib, sorafenib or both received either everolimus (272 patients) or placebo (138). Median progression-free survival was 4.0 months with everolimus and 1.9 months with placebo, and the trial was stopped early. Common side effects were mouth sores, rash and fatigue, and 8% of treated patients developed pneumonitis.
This was one of the first large randomised trials to show that blocking mTOR helps cancer patients, and it supported the use of everolimus after other targeted drugs fail.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2007 | H | Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma HUD2007 Senior author (Global ARCC trial): temsirolimus extended survival to 10.9 vs 7.3 months with interferon in poor-prognosis kidney cancer (phase 3, humans). |
| 2008 | H | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial MOT2008 First author of RECORD-1, the double-blind phase III trial in which everolimus roughly doubled progression-free survival (4.0 vs 1.9 months) in metastatic renal cell carcinoma. |
Co-authors in the Atlas 2
People with a profile here who share at least one study with Robert J. Motzer.
ShowHide
- David Lebwohl Medical oncologist and drug developer who led the clinical development of everolimus (Afinitor) at Novartis through approvals in several cancers and tuberous sclerosis, and later served as Chief Medical Officer of the gene-editing company Intellia Therapeutics
- Gary Hudes Medical oncologist at Fox Chase Cancer Center who led the phase 3 trial showing that the mTOR inhibitor temsirolimus lengthens survival in poor-prognosis advanced kidney cancer
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.